Interpace Biosciences Announces New Draft LCD and Reimbursement for Its Proprietary Thyroid Assay, ThyGeNEXT®
17 déc. 2019 06h55 HE
|
Interpace Biosciences, Inc.
Parsippany, NJ, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced that its Medicare Administrative Contractor (MAC) has issued a new draft local coverage...
Interpace Biosciences Launches New Corporate Website
02 déc. 2019 06h55 HE
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (IDXG) announced today that it is launching its new corporate website, “Interpace.com”. Now both the Diagnostics and...
Interpace to Present Data at the ATA Annual Meeting
29 oct. 2019 06h55 HE
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Interpace (IDXG) announced today that it will be presenting new data on the performance of its molecular thyroid products at the upcoming 89th...
Interpace to Present at the American College of Gastroenterology Conference
24 oct. 2019 06h55 HE
|
Interpace Diagnostics Group, Inc.
Interpace hosts 2nd Annual Fellow Programs PARSIPPANY, NJ, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Interpace (IDXG) announced today that it will be presenting new data on the performance of its...
Interpace Announces Closing of $13 Million Second Tranche Acquisition Financing from Ampersand Capital Partners
17 oct. 2019 06h55 HE
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, Oct. 17, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (IDXG) announced today that it has closed on a $13 million Convertible Preferred Stock investment by Ampersand...
Interpace Diagnostics Enters Agreement with Predictive Oncology to Enhance Diagnosis of Thyroid Cancer Via AI-Driven Analysis
18 juil. 2019 06h55 HE
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, July 18, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (“Interpace” or the “Company), announced today that it has executed an agreement with the Helomics...
Interpace Diagnostics Acquires Cancer Genetics’ Biopharma Services Business Supported by Investment from Ampersand Capital Partners
15 juil. 2019 16h10 HE
|
Interpace Diagnostics Group, Inc.
Conference Call to be Held Tomorrow, Tuesday July 16, 2019 @ 8:30 am ET PARSIPPANY NJ, July 15, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (“Interpace” or the...
Interpace Diagnostics Announces Presentation at the World Congress on Thyroid Cancer
13 juin 2019 06h55 HE
|
Interpace Diagnostics Group, Inc.
Rome, ITALY, June 13, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG), a fully integrated bioinformatics and commercial molecular diagnostic company, today announced that...
Interpace Diagnostics BarreGEN® Data to be Presented at Digestive Disease Week
09 mai 2019 06h55 HE
|
Interpace Diagnostics Group, Inc.
Company to Host Fellowship and Key Opinion Leader Programs PARSIPPANY, NJ, May 09, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that data from an...
Interpace Diagnostics Group Reports Full Year and Fourth Quarter 2018 Financial Results
19 mars 2019 16h05 HE
|
Interpace Diagnostics Group, Inc.
Business Progress and Recent Accomplishments Highlighted and Discussed Further on Conference Call PARSIPPANY, NJ, March 19, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ:...